The lower expression of ALDH1A1 clearly identifies a crucial deficiency of AML cells and a potential vulnerability: DIMATE, in the pharmaceutical form of ABD-3001, is currently under study for relapsed and refractory AML in the clinical trial ‘ODYSSEY’ (NCT05601726). The gene discussed is ALDH1A1; the disease is acute myeloid leukemia.